Tag: Initial Public Offering (IPO)
UPDATED: Apnimed files for IPO, FDA accepts application
July 14, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC). The company has also announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application filing for Oxnimbi, an oral treatment for obstructive sleep apnea (OSA).
In its Form S-1, the company acknowledges positive airway pressure (PAP) as the current standard of care for OSA, but notes many patients refuse or discontinue the treatment...
In brief: Apnimed files for IPO, BMC receives warning, Quality Biomed makes buy
July 10, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has filed for an initial public offering (IPO) and announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application filing for Oxnimbi, an oral treatment for obstructive sleep apnea (OSA).
In its Form S-1, the company acknowledges positive airway pressure (PAP) as the current standard of care for OSA, but notes many patients refuse or discontinue the treatment due to issues such as discomfort, pressure intolerance and...
McKesson moves MMS closer to IPO
May 15, 2026Liz Beaulieu, Editor
IRVING, Texas – McKesson’s Medical-Surgical Solutions (MMS) segment is now operationally and legally separate, and with new financing and a new minority ownership, it is closer to becoming financially independent, says CFO Britt Vitalone.
In early April, the company announced:
A $1 billion revolving credit facility and the issuance of $1 billion in Term Loan A facilities.
The sale of a 13% minority interest to funds managed by Apollo in a deal that values the segment at $13...
McKesson sells stake in Medical-Surgical Solutions
April 29, 2026HME News Staff
IRVING, Texas – McKesson has taken another step toward separating its Medical-Surgical Solutions (MMS) business by selling a minority interest to funds managed by Apollo.
Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest, valuing the business at approximately $13 billion.
“This transaction marks a key milestone in McKesson’s planned separation of MMS,” said Brian Tyler, CEO of McKesson. “We...
Medtronic’s MiniMed joins Nasdaq
March 17, 2026HME News Staff
GALWAY, Ireland, and NORTHRIDGE, Calif. – MiniMed Group, a subsidiary of Medtronic, has begun trading on the Nasdaq under the ticker symbol “MMED” in connection with its initial public offering (IPO). "Today marks an exciting milestone for both MiniMed and Medtronic,” said Geoff Martha, Medtronic chairman and CEO. “Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest...
Medline closes IPO, trades at $42.78
December 29, 2025HME News Staff
NORTHFIELD, Ill. - Medline announced Dec. 18 that it closed its upsized initial public offering (IPO) of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 32,405,172 shares of Class A common stock. Medline intends to use the proceeds (net of underwriting discounts) from the issuance of 179,000,000 shares to repay outstanding indebtedness...
Medtronic starts IPO process for MiniMed
December 23, 2025HME News Staff
GALWAY, Ireland – Medtronic has announced that its diabetes business, which will operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be completed through a series of capital markets transactions, with a preferred path of an IPO and subsequent split-off. MiniMed intends...
Medline to start trading at $29
December 18, 2025HME News Staff
NORTHFIELD, Ill. – Medline Inc. on Dec. 17 was expected to begin trading shares on the Nasdaq Global Select Market under the symbol “MDLN” at an initial public offering of $29 per share. The upsized IPO is for 216,034,482 shares of its Class A common stock; Medline has granted the underwriters a 30-day option to purchase up to an additional 32,405,172 shares of Class A common stock. The company plans to use the proceeds (net of underwriting...
In brief: Final rule delay, Medline IPO, HME Appreciation Week, Philips earnings
November 5, 2025HME News Staff
WASHINGTON – A final rule with further details about CMS’s next round of the competitive bidding program (CBP) was not released last week, giving industry stakeholders more time to continue advocacy efforts, AAHomecare says.
The 2026 DMEPOS/Home Health Final Rule final rule was expected to be released on Oct. 31.
“Whether that delay is tied to the HME community’s all-out advocacy efforts on CBP provisions...
Medline officially files for IPO
November 3, 2025HME News Staff
NORTHFIELD, Ill. - Medline has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed public offering of its common stock.
The number of shares to be offered and the price range and other terms for the offering have not yet been determined. If the offering is completed, Medline intends to list its stock on the Nasdaq Global Select Market under the symbol “MDLN.” Goldman Sachs & Co. LLC, Morgan Stanley,...